Showing 1716 results
-
Press release /Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas…
-
Press release /New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
-
Press release /Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea…
-
Press release /FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible Using patients' self-recorded measurements, FocalView aims to…
-
In The News /Novartis Chief Digital Officer Bertrand Bodson says tech professionals don’t need a background in biology to switch industries.
-
In The News /Novartis Chief Digital Officer Bertrand Bodson talked to FiercePharma about pharma’s COVID-19 pandemic reputation boost with potential tech hires.
-
In The News /In this episode of CNN`s special HR series, Steven Baert, Chief People & Organization Officer, shares the challenges that Novartis is facing as it turns its management style on its head and…
-
Press release /Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying topical treatment for presbyopia patients…
-
Ad hoc release /If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9…
-
Webform /Complete the form below to submit your medical enquiry. Our Medical Information team will respond to your request as soon as possible. This request form is intended for healthcare professionals (…